BYSI — BeyondSpring Inc.
$0.60
+$0.00 (+0.03%)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Market Cap
$24.72M
Forward P/E
-1.3x
52-Week Range
N/A
BYSI Price History
Revenue vs. Net Income
$1.4M
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$28.2M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-92.9%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.9x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.5%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
39.1M
Diluted shares · FY2022
Only one year of share data is available, so no change can be shown yet.
